CEO Martin Nicklasson leaves Swedish Orphan Biovitrum

CEO Martin Nicklasson leaves Swedish Orphan Biovitrum


Stockholm, Sweden November 25, 2010 - Swedish Orphan Biovitrum (STO:SOBI) today announced that CEO Martin Nicklasson will leave the company. The search for a new CEO will be initiated immediately. Kennet Rooth, currently head of marketing and sales, has agreed to assume the position as interim CEO for SOBI.

 

Based upon the growth aspirations, the emerging late stage clinical development pipeline and the continuous increasing commercial portfolio, Swedish Ophan Biovitrum is entering into a new phase in its development. Therefore, the board of directors initiated a dialogue with CEO Martin Nicklasson regarding the profile needed to match the next phase the company is entering into. The Board of Directors and Martin Nicklasson have jointly come to the conclusion that a new leadership is desired for the company going forward. Kennet Rooth, currently Head of Sales and Marketing, has agreed to stay with the company and assume the position as interim CEO for SOBI until a new CEO has been recruited. Martin Nicklasson will leave SOBI on January 1, 2011.

"On the behalf of the whole board we want to express our gratitude to the excellent job that Martin Nicklasson has done over the last 3 years. Martin has been material in transforming Biovitrum from a research company focusing on small molecular drugs, to become a niche specialty pharma leader in the field of rare diseases with an attractive pipeline of biological drugs. With the recent acquisition and integration of Swedish Orphan International, Martin hands over a well-reputed leading international company and a platform to build further on", says SOBI's Chairman Bo Jesper Hansen.

"After the successful transformation of Biovitrum, followed by the creation of SOBI, now is a good time for a new leader to take the company forward into the future. I will now have the opportunity to evaluate different non-executive opportunities, says Martin Nicklasson.

For more information please contact Bo Jesper Hansen, Chairman of the Board Phone: +46 767 82 02 83

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based orphan drug niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients and for patients with high unmet medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com<http://www.sobi.com/>.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on November 25, 2010 at 8:30 a.m. CET.

Press release November 25 in PDF format<http://hugin.info/134557/R/1465404/403605.pdf>

 

 

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.